Skip to main content
. 2017 Jul 14;49(10):1867–1873. doi: 10.1007/s11255-017-1655-2

Table 1.

Clinical characteristics of the patients at the beginning of the study

Parameter Spironolactone group (n = 22) Control group (n = 15) p
Age (years) 54.57 ± 13.78 51.14 ± 18.72 0.70
BMI (kg/m2) 25.16 ± 3.58 24.05 ± 4.42 0.61
Time on PD at the onset of the study (months) 25.28 ± 9.46 20.42 ± 10.69 0.38
Hemoglobin concentration (g/dl) 11.45 ± 0.97 11.55 ± 1.39 0.65
Serum calcium (mmol/l) 2.29 ± 0.24 2.28 ± 0.13 0.28
Serum phosphorus (mmol/l) 1.60 ± 0.30 1.75 ± 0.58 0.55
PTH (pg/ml) 306.00 (125.0;759.0) 376.00 (98.0;805.0) 0.22
Serum albumin (g/dl) 4.17 ± 0.23 3.99 ± 0.20 0.60
Urine volume (ml/day) 914.28 ± 94.49 878.57 ± 191.17 0.66
UF volume (ml/day) 872.85 ± 96.55 910 ± 134.90 0.56
PET
 H 7 5 0.14
 HA 12 8 0.34
 LA 3 2 0.54
 L 0 0

Normally distributed data are expressed as mean ± SD, and not normally distributed data are expressed as median ± IQR

BMI body mass index, PET peritoneal equilibration test, UF ultrafiltration, PTH parathormone, PD peritoneal dialysis; H high, HA high average, LA low average, L low